BAYER AG

Asia Deal Watch: Kaken acquires Aadi subsidiary and cancer drug Fyarro. Other deals include Hangzhou DAC/Aadi, Astellas/Sangamo, Kyorin/Bayer, Eisai/Newron, Lupin/Boehringer Ingelheim, Asahi Kasei/Chiome.

Aspargo Labs appoints Álvaro Fernández in Spain and Dr. Marc van Unen in Germany to accelerate global expansion, leveraging their pharmaceutical industry expertise.

Aspargo Labs appoints Álvaro Fernández and Dr. Marc van Unen as General Managers in Spain and Germany to drive global expansion. Both bring extensive pharmaceutical experience to accelerate the company's international growth.

2024 saw major medical advancements: FDA approved Orlynvah for UTIs, Cobenfy for schizophrenia, and Miplyffa/Aqneursa for Niemann-Pick disease type C. Bayer's elinzanetant showed promise for hot flashes.

The 'Macular Edema - Global Clinical Trials Review, 2024' report by ResearchAndMarkets.com offers an overview of global clinical trials on Macular Edema, including trial numbers, enrollment, regions, countries, phases, statuses, and sponsor types. It highlights prominent drugs and companies involved, and provides enrollment trends and recent news.

Bayer's QUASAR study showed aflibercept 8 mg, given every 8 weeks after initial monthly doses, achieved non-inferior visual acuity gains vs. Eylea 2 mg every 4 weeks in RVO patients. Aflibercept 8 mg demonstrated sustained disease control, rapid fluid reduction, and fewer injections with similar efficacy and safety. It's approved in over 50 countries for nAMD and DME, offering up to 5-month treatment intervals.

Cancer trials face a 95% failure rate despite advancements like CAR T-cell therapies. Nuclear isotopes, used for imaging and therapy, show promise in targeting cancer cells while sparing healthy tissues. Actinium-225 and Lutetium-177 are particularly promising, with challenges including supply, delivery precision, and patient-specific dosing. AI could optimize isotope production, delivery, and personalized treatment plans, though data limitations and high costs remain significant hurdles.

The US biosimilar market surged in 2024, driven by FDA approvals and looming patent cliffs, with 63 biosimilars approved and 42 launched. Innovator companies like Novartis, Biogen, Pfizer, and Amgen are entering biosimilar development to mitigate sales erosion. Challenges include market access, reimbursement barriers, and HCP/patient perception. Education and transparency are crucial for biosimilar adoption, with AI tools potentially aiding HCPs.

Bayer announced positive phase III QUASAR study results for aflibercept 8 mg, showing non-inferior visual acuity gains compared to Eylea™ 2 mg in retinal vein occlusion patients, with extended treatment intervals and a well-tolerated safety profile. Aflibercept 8 mg has potential as a new standard of care for exudative retinal diseases, offering less frequent injections at comparable efficacy and safety.